Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GoodRx Holdings, Inc.GDRX · Entity 4838 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GoodRx Holdings, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 343,810 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 73,434 · Balance 343,810 F1: Reflects restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Class A common stock. The restricted stock units vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 and (ii) the date of the 2027 Annual Meeting of Stockholders, subject to Reporting Person's continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy TB 2024-2 GRAT | 543,377 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 543,377 F2: Share held directly by TB 2024 -2 GRAT, a grantor retained annuity trust (the "TB 2024-2 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the TB 2024-2 GRAT. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy TB 2025 GRAT | 2,089,343 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,089,343 F3: Share held directly by TB 2025 GRAT, a grantor retained annuity trust (the "TB 2025 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the TB 2025 GRAT. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1 |
| Class A Common StockSEC Table I · non-derivative | IndirectBy JB 2024-2 GRAT | 543,377 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 543,377 F4: Share held directly by JB 2024-2 GRAT, a grantor retained annuity trust (the "JB 2024-2 GRAT"). Jana Bezdek, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the TB 2024-2 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the TB 2024-2 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy JB 2025 GRAT | 2,089,343 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,089,343 F5: Share held directly by JB 2025 GRAT, a grantor retained annuity trust (the " JB 2025 GRAT"). Jana Bezdek, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the JB 2025 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the JB 2025 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Class A common stock. The restricted stock units vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 and (ii) the date of the 2027 Annual Meeting of Stockholders, subject to Reporting Person's continued service through the applicable vesting date.
F2: Share held directly by TB 2024 -2 GRAT, a grantor retained annuity trust (the "TB 2024-2 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the TB 2024-2 GRAT.
F3: Share held directly by TB 2025 GRAT, a grantor retained annuity trust (the "TB 2025 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the TB 2025 GRAT.
F4: Share held directly by JB 2024-2 GRAT, a grantor retained annuity trust (the "JB 2024-2 GRAT"). Jana Bezdek, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the TB 2024-2 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the TB 2024-2 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares.
F5: Share held directly by JB 2025 GRAT, a grantor retained annuity trust (the " JB 2025 GRAT"). Jana Bezdek, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the JB 2025 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the JB 2025 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2022 Filed Dec 5, 2022 21:47 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 129,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037637 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 129,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:47 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 127,220 | $4.36 | $554,679.20 |
DisclosureSEC source: 0000899243-22-037637 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,374 Underlying: Class A Common Stock · 127,220 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:47 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037637 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,594 Underlying: Class A Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:47 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037637 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,796,162 Underlying: Class B Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. F2 · derivative.expiration_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:47 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 129,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037637 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 129,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030427 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 129,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 127,220 | $6.10 | $776,042.00 |
DisclosureSEC source: 0000899243-22-030427 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,374 Underlying: Class A Common Stock · 127,220 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030427 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,594 Underlying: Class A Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030427 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,052,756 Underlying: Class B Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock F2 · derivative.exercise_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. F2 · derivative.expiration_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 129,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030427 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 22:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 129,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020740 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 129,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 22:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 127,220 | $7.97 | $1,013,943.40 |
DisclosureSEC source: 0000899243-22-020740 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,375 Underlying: Class A Common Stock · 127,220 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 22:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020740 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,595 Underlying: Class A Common Stock · 256,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 22:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020740 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,309,350 Underlying: Class B Common Stock · 256,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. F2 · derivative.expiration_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 22:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 129,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020740 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:32 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 134,716 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009232 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 134,716 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:32 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 121,878 | $27.40 | $3,339,457.20 |
DisclosureSEC source: 0000899243-22-009232 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,716 Underlying: Class A Common Stock · 121,878 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:32 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009232 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,594 Underlying: Class A Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:32 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009232 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,565,945 Underlying: Class B Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. F2 · derivative.expiration_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:32 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 134,716 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009232 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 23:07 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 65,104 | $33.98 | $2,212,383.66 |
DisclosureSEC source: 0000899243-21-049659 · doc4.xml · nonDerivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,968 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020 and amended on September 1, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.61 to $34.56, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:07 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 64,271 | $35.19 | $2,261,535.81 |
DisclosureSEC source: 0000899243-21-049659 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,072 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020 and amended on September 1, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.90 to $35.65, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:26 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 129,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-046787 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 129,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:26 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 127,220 | $39.92 | $5,078,622.40 |
DisclosureSEC source: 0000899243-21-046787 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,375 Underlying: Class A Common Stock · 127,220 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:26 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-046787 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,595 Underlying: Class A Common Stock · 256,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:26 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-046787 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,822,539 Underlying: Class B Common Stock · 256,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. F2 · derivative.expiration_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:26 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 129,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-046787 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 20:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 400 | $43.58 | $17,433.00 |
DisclosureSEC source: 0000899243-21-038075 · doc4.xml · nonDerivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,968 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.47 to $43.73, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 20:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 4,604 | $42.95 | $197,746.40 |
DisclosureSEC source: 0000899243-21-038075 · doc4.xml · nonDerivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,368 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.44 to $43.38, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 20:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 900 | $46.10 | $41,490.36 |
DisclosureSEC source: 0000899243-21-038075 · doc4.xml · nonDerivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,972 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.89 to $46.36, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 20:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 6,912 | $45.24 | $312,678.84 |
DisclosureSEC source: 0000899243-21-038075 · doc4.xml · nonDerivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,872 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.87 to $45.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 20:37 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 116,558 | $44.24 | $5,156,117.97 |
DisclosureSEC source: 0000899243-21-038075 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.87 to $44.85, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Prior to the reported transaction, the Reporting Person held 260,342 shares of Class A Common Stock, rather than 391,408 shares of Class A Common Stock. The Reporting Person's prior Form 4 inadvertently included 131,066 shares that had been sold on March 22, 2021 and reported in a Form 4 filed on March 24, 2021. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 129,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-035101 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 129,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 127,220 | $37.11 | $4,721,134.20 |
DisclosureSEC source: 0000899243-21-035101 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,374 Underlying: Class A Common Stock · 127,220 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-035101 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,594 Underlying: Class A Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-035101 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,079,134 Underlying: Class B Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. F2 · derivative.expiration_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 129,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-035101 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 34,520 | $38.49 | $1,328,512.56 |
DisclosureSEC source: 0000899243-21-026259 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,034 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.03 to $39.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:11 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 56,026 | $38.32 | $2,146,899.51 |
DisclosureSEC source: 0000899243-21-025730 · doc4.xml · nonDerivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,554 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.74, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:11 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 38,829 | $37.49 | $1,455,516.71 |
DisclosureSEC source: 0000899243-21-025730 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,580 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.96 to $37.94, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:29 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 129,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021636 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 129,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:29 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 127,220 | $37.11 | $4,721,134.20 |
DisclosureSEC source: 0000899243-21-021636 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,375 Underlying: Class A Common Stock · 127,220 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:29 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021636 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,595 Underlying: Class A Common Stock · 256,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:29 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021636 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,335,728 Underlying: Class B Common Stock · 256,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. F2 · derivative.expiration_date: The restricted stock units vested or will vest in 16 equal quarterly installments that commenced on September 1, 2020. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:29 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 129,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021636 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 21:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 44,766 | $37.47 | $1,677,552.13 |
DisclosureSEC source: 0000899243-21-013307 · doc4.xml · nonDerivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,968 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.33 to $37.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 21:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 84,600 | $37.00 | $3,130,132.32 |
DisclosureSEC source: 0000899243-21-013307 · doc4.xml · nonDerivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,734 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.33 to $37.32, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 21:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 1,700 | $35.85 | $60,942.96 |
DisclosureSEC source: 0000899243-21-013307 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,334 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 125,528 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008976 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 131,066 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 125,528 | $46.13 | $5,790,606.64 |
DisclosureSEC source: 0000899243-21-008976 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,066 Underlying: Class A Common Stock · 125,528 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.